1,7-二甲基苯并咪唑-2-胺 | 945021-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1,7-二甲基苯并咪唑-2-胺
• 中文别名: 1,7-二甲基-2-氨基苯并咪唑
• 英文名称: 1,7-Dimethyl-1H-benzo[d]imidazol-2-amine
• 英文别名: 1,7-dimethylbenzimidazol-2-amine
• CAS: 945021-49-8
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: HOMNAVGFMHNVBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2'-溴-4-氯苯乙酮 、 1,7-二甲基苯并咪唑-2-胺 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(4-Chlorophenyl)-2-(2-imino-3,4-dimethylbenzimidazol-1-yl)ethanone
  参考文献：
  名称：

  Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3

  摘要：

  High-throughput screening identified a low molecular weight antagonist of CXCR3 displaying micromolar activity in a membrane filtration-binding assay. Systematic modi. cation of the benzimidazole core and tethered acetophenone moiety established tractable SAR of analogs with improved physicochemical properties and sub-micromolar activity across both human and murine receptors. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.074
• 作为产物：
  描述：

  2-氯-3-硝基甲苯 在 盐酸 、 氢气 、 铜 、 对甲苯磺酸 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 异丙醇 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 27.5h， 生成 1,7-二甲基苯并咪唑-2-胺
  参考文献：
  名称：

  Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action

  摘要：

  In this report we describe 2-iminobenzimidazole (IBI) analogs, identified during the course of a phenotypic high-throughput screening campaign, as novel hepatitis C virus (HCV) inhibitors. A series of IBI derivatives was synthesized and evaluated for their inhibitory activity against infectious HCV. Among the IBIs derivatives studied in this work, we identified promising compounds with high antiviral efficacy, high selectivity index and good microsomal stability. Noteworthy, the IBI series exhibited inhibitory activity on early and late steps of the viral cycle, but not in the HCV replicon system demonstrating a mechanism of action distinct from clinical-stage and approved anti-HCV drugs. Overall, our results suggest that IBIs are predestinated for further exploration as lead compounds for novel HCV interventions. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.030

文献信息

• 2-Imino-benzimidazoles
  申请人：Roth P. Gregory

  公开号：US20070232673A1

  公开（公告）日：2007-10-04

  Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  本发明涉及式（I）的新化合物或其药学上可接受的盐、前药和生物活性代谢物，其中取代基如本文所定义，其作为治疗剂具有用处。
• Toll-like receptor agonists
  申请人：The University of Kansas

  公开号：US10471139B2

  公开（公告）日：2019-11-12

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.

  本文所述化合物可用于治疗目的。这些化合物可以是 TLR 激动剂，如 TLR7 或 TLR8 激动剂。这些化合物可包含在药物组合物中，用于治疗TLR激动剂有用的疾病。药物组合物可以包括任何成分，例如药物组合物中常见的载体、稀释剂、赋形剂、填料等。化合物可以是本文图示或描述的化合物，也可以是其衍生物、原药、盐或立体异构体，或在任何手性中心具有任何手性的化合物，或同系物、多晶型物、溶胶或其组合。因此，这些化合物可用作疫苗佐剂，也可用于本文所述的其他治疗目的。这些化合物可以具有任意一个式子。化合物的实例可参见表 1 和表 A1 中的活化剂。
• [EN] 2-IMINO-BENZIMIDAZOLES<br/>[FR] 2-IMINO-BENZIMIDAZOLES
  申请人：ABBOTT LAB

  公开号：WO2007084728A2

  公开（公告）日：2007-07-26

  [EN] Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I), wherein the substituents are as defined herein, which are useful as therapeutic agents.
  [FR] Cette invention concerne de nouveaux composés représentés par la formule (I) ou des sels pharmaceutiquement acceptables, des promédicaments et des métabolites biologiquement actifs de ces composés représentés par la formule (I) dans laquelle les substituants sont tels que définis dans la description, lesquels composés sont utilisés comme agents thérapeutiques.
• Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3
  作者：Martin E. Hayes、Grier A. Wallace、Pintipa Grongsaard、Agnieszka Bischoff、Dawn M. George、Wenyan Miao、Michael J. McPherson、Robert H. Stoffel、David W. Green、Gregory P. Roth

  DOI：10.1016/j.bmcl.2008.01.074

  日期：2008.3

  High-throughput screening identified a low molecular weight antagonist of CXCR3 displaying micromolar activity in a membrane filtration-binding assay. Systematic modi. cation of the benzimidazole core and tethered acetophenone moiety established tractable SAR of analogs with improved physicochemical properties and sub-micromolar activity across both human and murine receptors. (c) 2008 Elsevier Ltd. All rights reserved.
• Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action
  作者：Marc Peter Windisch、Suyeon Jo、Hee-Young Kim、Soo-Hyun Kim、Keumhyun Kim、Sunju Kong、Hyangsuk Jeong、Sujin Ahn、Zaesung No、Jong Yeon Hwang

  DOI：10.1016/j.ejmech.2014.03.030

  日期：2014.5

  In this report we describe 2-iminobenzimidazole (IBI) analogs, identified during the course of a phenotypic high-throughput screening campaign, as novel hepatitis C virus (HCV) inhibitors. A series of IBI derivatives was synthesized and evaluated for their inhibitory activity against infectious HCV. Among the IBIs derivatives studied in this work, we identified promising compounds with high antiviral efficacy, high selectivity index and good microsomal stability. Noteworthy, the IBI series exhibited inhibitory activity on early and late steps of the viral cycle, but not in the HCV replicon system demonstrating a mechanism of action distinct from clinical-stage and approved anti-HCV drugs. Overall, our results suggest that IBIs are predestinated for further exploration as lead compounds for novel HCV interventions. (C) 2014 Elsevier Masson SAS. All rights reserved.